Livalo Approval History
- FDA approved: Yes (First approved August 3rd, 2009)
- Brand name: Livalo
- Generic name: pitavastatin
- Company: Kowa Company, Ltd.
- Treatment for: High Cholesterol
Livalo (pitavastatin) is an HMG CoA reductase inhibitor indicated for the primary treatment of hypercholesterolemia and combined dyslipidemia.
Development History and FDA Approval Process for Livalo
|Aug 4, 2009||FDA Approves Livalo for Primary Hypercholesterolemia and Combined Dyslipidemia|
|Oct 28, 2008||Kowa Announces NDA Submission and MAA Filing for HMG CoA Reductase Inhibitor Pitavastatin|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.